PYPD PYPD
Company Profile ↓Company Overview
PYPD (PYPD) is a publicly traded company listed on with a market capitalization of $83.74M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.25.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +33.72% |
| 6 Months: | -2.95% |
| 3 Months: | +2.22% |
| 1 Month: | -13.70% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)50.85 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 7.58M | 9.40M | 7.46M | 8.53M | 7.76M |
| Operating Income | - | -7.58M | -9.40M | -7.46M | -8.53M | -7.76M |
| EBITDA | - | -7.58M | -9.40M | -7.46M | -8.85M | -7.76M |
| Interest Expense | 286.00K | 678.00K | 521.00K | - | - | - |
| Pretax Income | - | -8.26M | -9.92M | -7.43M | -8.55M | -7.73M |
| Tax Provision | - | 11.00K | 53.00K | 22.00K | -81.00K | 0 |
| Net Income | - | -8.27M | -9.98M | -7.45M | -8.47M | -7.73M |
| Diluted EPS | - | -0.70 | -0.78 | -0.37 | -0.41 | -0.35 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 38.89M | 22.87M | 28.03M | 32.97M |
| Operating Income | - | -38.89M | -22.87M | -28.03M | -32.97M |
| EBITDA | - | -37.17M | -20.36M | -25.85M | -31.83M |
| Interest Expense | - | 540.00K | 1.62M | 1.51M | 874.00K |
| Pretax Income | - | -39.43M | -23.80M | -28.98M | -34.16M |
| Tax Provision | - | 129.00K | 69.00K | 42.00K | 5.00K |
| Net Income | - | -39.56M | -23.86M | -29.02M | -34.17M |
| Diluted EPS | - | -60.90 | -16.99 | -4.91 | -2.09 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 25.97M | 15.37M | 25.22M | 22.31M |
| Current Assets | - | 14.19M | 6.07M | 16.57M | 15.23M |
| Cash & Equivalents | - | 8.55M | 5.31M | 15.64M | 6.40M |
| Inventory | - | - | - | 0 | 1.11M |
| Receivables | 118.00K | 298.00K | - | - | - |
| Total Liabilities | - | 20.14M | 17.47M | 17.54M | 11.33M |
| Current Liabilities | - | 8.55M | 7.29M | 12.68M | 7.74M |
| Long Term Debt | - | 7.57M | 6.38M | 634.00K | - |
| Total Debt | - | 13.73M | 11.78M | 9.62M | 2.80M |
| Total Equity | - | 5.83M | -2.10M | 7.68M | 10.97M |
| Shares Outstanding | - | 661.73K | 1.65M | 10.19M | 18.20M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -34.32M | -17.24M | -21.96M | -27.88M |
| Investing Cash Flow | - | 16.57M | 3.80M | -330.00K | -6.70M |
| Financing Cash Flow | - | 16.43M | 9.98M | 32.42M | 25.37M |
| Capital Expenditure | - | -1.77M | -196.00K | -76.00K | -210.00K |
| Free Cash Flow | - | -36.08M | -17.43M | -22.04M | -28.09M |
| Net Change in Cash | - | -1.31M | -3.46M | 10.12M | -9.21M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -678.6% | 1,138.6% | -377.7% | -311.4% |
| ROCE % | - | -223.3% | -282.8% | -223.5% | -226.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PYPD
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
PETACH TIKVA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right wh…
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company’s previously communicated guidance FDA identified no Filing review issues Acceptance triggers $15 million milestone payment, completing $30 million in…
Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid
Woburn, MA, July 21, 2026 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, a privately held specialty pharmaceutical company, today announced plans to commercialize D-PLEX100 upon approval in the United States and Canada for the prevention of a…
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentagesAzurity, a private…
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
If approved, D-PLEX100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -…
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right whe…
PYPD — Frequently Asked Questions
What is the current share price of PYPD?
As of 2026-08-05 17:25 PDT, PYPD trades at $4.60 on NASDAQ/NYSE. Its 52-week range is $3.15 to $5.58.
What is the market capitalisation of PYPD?
PYPD has a market capitalisation of $83.74M on NASDAQ/NYSE.
What is the P/E ratio of PYPD?
PYPD trades at a trailing price-to-earnings (P/E) ratio of -2.20. Its price-to-book (P/B) ratio is 7.63.
Is PYPD a good stock to buy?
This page provides a data-driven analysis of PYPD, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.